Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Marshall Schreeder (NPI 1083693154)

Field	Value
Entity Type	Individual
Organization	Marshall Schreeder
Address	3601 Cci Dr Nw
City	Huntsville
State	AL
ZIP	35805
Taxonomy	Medical Oncology Physician
NPI Enumerated	January 17, 2006

Payer Source	Total Paid
Medicare	$3.5M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: total Medicare revenue is $3.5M and there is no Medicaid billing on file, so Medicare drives all recorded public-payer activity for this NPI. Analysts should treat this profile as Medicare-centric when evaluating utilization or contracting exposure.

Revenue is highly concentrated: the precomputed top three Medicare codes account for 74.6% of the provider's Medicare revenue, led by J9271 at $1.6M (47.5% of Medicare revenue), followed by J9299 at $583.3K (17.6%) and J0897 at $314.6K (9.5%). This concentration indicates that a small set of biologic/immunotherapy agents dominate the practice’s billing.

The code mix and volumes point to an infusion-focused oncology practice centered on immunotherapy and supportive cancer care: large volumes of J9271 (pembrolizumab) and J9299 (nivolumab) combined with chemo administration codes such as 96413 (747 claims, $68.7K, 2.1%) and supportive agents like Q5127 (708 claims, $190.5K, 5.7%) suggest on-site infusions, follow-up E/M visits, and associated supportive medications are core services.

Competitive standing by code is divergent: for J9271 the provider ranks #47 of 1841 nationally (97th percentile) and is described as notably above typical national volume, indicating a major national presence for pembrolizumab use; J0897 also ranks highly at #432 of 10057 (96th percentile; notably above typical national volume). By contrast, J9299 sits at #103 of 505 (80th percentile; typical, unremarkable volume), so the provider is a top-volume outlier for some drugs but not uniformly dominant across all immunotherapies.

High visit and ancillary-service volumes support ongoing longitudinal oncology care: 99214 shows 1.2K claims with $102.9K revenue (3.1%) and ranks #7890 of 479517 (98th percentile; labeled an extreme outlier), while 99215 (406 claims, $53.2K, 1.6%) ranks #3153 of 145531 (98th percentile; notably above typical national volume). Frequent lab codes (80053, 85025, 36415 each in the thousands of claims and ranking in high percentiles) further corroborate an active office-based treatment and monitoring workflow.

Several CPT/HCPCS codes are flagged as statistical outliers or notably above typical national volume and should be monitored for utilization patterns: 96413 ranks #217 of 7514 (97th percentile; notably above typical national volume) and 96375 ranks #188 of 5191 (96th percentile; notably above typical national volume), reflecting above-average procedural throughput for chemotherapy administration and IV medication handling. These labels indicate intensity of infusion services rather than any implication about intent.

Tenure and stability metrics: the provider’s NPI was enumerated on 2006-01-17 (~20 years ago), which points to a long-tenured practice likely with established referral patterns and operational processes that support sustained high-volume infusion activity. Longevity reinforces that the observed code mix is likely structural rather than transient.

Implications for payers and network managers: with $1.6M in Medicare revenue concentrated on J9271 and the top three codes making up 74.6% of Medicare dollars, the provider presents concentrated spend risk tied to high-cost biologics and infusion utilization. Given the absence of Medicaid billing, payer negotiation or utilization management efforts should primarily focus on Medicare coverage and medical‑necessity protocols for high-volume immunotherapies and associated administration services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

96 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	36,600	$40	$1.6M
J9299	Injection, nivolumab, 1 mg	25,360	$20	$583.3K
J0897	Injection, denosumab, 1 mg	16,560	$20	$314.6K
Q5127	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	710	$270	$190.5K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,440	$30	$117K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,160	$90	$102.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	750	$90	$68.7K
J1437	Injection, ferric derisomaltose, 10 mg	3,700	$20	$59.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	410	$130	$53.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	120	$340	$38.5K

Showing 1–10 of 96

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 96 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Marshall Schreeder — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

96 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	30	19,900	$40	$827.2K
J9299	2	10	19,060	$20	$535.1K
J1568	29	30	5,180	$30	$316.2K
Q5127	6	20	590	$270	$165.7K
J0897	12	200	3,120	$20	$97.7K
J1437	16	40	3,000	$20	$59.1K
Q5108	8	10	370	$100	$38.1K
J1454	7	20	90	$340	$33.7K
J0881	9	30	7,720	$1	$24.1K
J9217	49	50	130	$130	$22.4K

Showing 1–10 of 96

Related Providers

Other providers that share a Tax Identification Number (TIN) with Marshall Schreeder, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
John Waples	AL	Medical Oncology Physician	$9.6M	$0
Heather Brody	AL	Hematology & Oncology Physician	$3.1M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Naveen Lobo	AL	Medical Oncology Physician	$2.4M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Daniel Schreeder	AL	Hematology & Oncology Physician	$2.3M	$0
Robert Conry	AL	Hematology & Oncology Physician	$2.1M	$0
Lakshmikanth Katragadda	AL	Hematology & Oncology Physician	$2.1M	$0
Oncology Specialties, P.C.	AL	Hematology & Oncology Physician	$0	$2M
Surrinder Dang	AL	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Marshall Schreeder, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Huntsville Emergency Medical Services, Inc.	AL	Land Ambulance	$5.6M	$6M
Madison Core Laboratories, LLC	AL	Clinical Medical Laboratory	$1.5M	$4M
Hc Healthcare, LLC	AL	Community Based Hospice Care Agency	$0	$4.8M
The Village Medical Clinic	AL	Specialist	$0	$2M
Ehab El-bahesh	AL	Hematology & Oncology Physician	$1.7M	$0
Pathology Associates, P.C.	AL	Anatomic Pathology & Clinical Pathology Physician	$0	$1.7M
Rehabilitation & Neurological Services LLC	AL	Specialist	$0	$1.3M
Philip Mcgee	AL	Hematology & Oncology Physician	$1.2M	$0
John Nicholson	AL	Hematology & Oncology Physician	$1.2M	$0
Elizabeth Falkenberg	AL	Radiation Oncology Physician	$1.1M	$0

Marshall Schreeder — Billing Profile & Reimbursement Data

Sign up for Marshall Schreeder — Billing Profile & Reimbursement Data policy alerts

Marshall Schreeder — Billing Profile & Reimbursement Data

Sign up for Marshall Schreeder — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References